GMR Solutions heads into mid-September with an unusual split: short sellers have been quietly tripling their positions, while the analyst community just raised the curtain on a bullish update from a top-tier bank.
The most striking data point this week is the pace of short interest accumulation. Shorts have grown roughly 320% since late July — from around 785,000 shares to 3.3 million — representing a fivefold build in just six weeks. The one-week jump alone is 25%, with the sharpest daily move coming on September 10, when shares short rose 21% in a single session. For a small-cap health care name with no percent-of-float figure readily available, that kind of velocity demands attention. The ORTEX short score reflects this: it jumped from a mid-range 51.8 at the start of last week to 58.8 by September 10, the highest reading in the recent history visible here, and it did so in a single day's leap rather than a gradual drift.
The lending market, however, tells a different story — and the contrast is the crux of this note. Despite the sharp rise in shares short, the borrow market remains loose. Availability is running at 489%, meaning there are nearly five shares available to borrow for every one currently lent out. That is tighter than it was a month ago, when availability was regularly above 1,000%, but it remains well inside the normal range and nowhere near squeeze territory. The 52-week tightest reading on availability was 241% — far below current levels. Cost to borrow has also eased, falling 14% over the week to just 1.38%, and is down 41% versus a month ago. The borrow market, in short, is accommodating new shorts without resistance. Positioning looks aggressive in direction but not yet crowded in mechanics.
The Street, meanwhile, moved in the opposite direction this week. JP Morgan's analyst raised his price target on GMRS from $15 to $16 on September 11 while maintaining an Overweight rating — a modest but directionally positive update from a bellwether firm. The broader analyst picture is uniformly constructive: when the stock received wide initial coverage in early June, every firm initiated at Buy, Outperform, or Overweight except Morgan Stanley, which came in at Equal-Weight with a $14 target. The mean price target across the group is $18.88, implying roughly 48% upside to the current $12.78 close. Note that one June initiation from Goldman Sachs carried a $35 target — a significant outlier that is not stale by date but sits far above the rest of the group; that figure may reflect a different valuation scenario and should be read with care. Stripping it out, the consensus range clusters between $14 and $20. Valuation multiples are undemanding: the stock trades at a P/E of 6.9x and an EV/EBITDA of 5.0x, with the EV/EBITDA multiple drifting slightly lower over the past month. The earnings yield has also ticked up. For a health care services business backed by KKR, the headline multiples look cheap relative to the analyst community's own targets.
The ownership picture is worth a brief note. KKR holds 19% of shares, with 81% of the company held through a vehicle called Pegasus Aggregator Holdco — so this is effectively still a KKR-sponsored name trading in the public market with limited true float. That structural fact matters for interpreting the short interest build: a large locked-up sponsor stake compresses the tradeable pool, which means even a few million shares short can represent a meaningful fraction of the liquid float. Several passive 13G filers — Fidelity, Norges Bank, Invesco, and North Peak — have all filed new positions between August and September, each holding around 4-6% of shares outstanding, suggesting the institutional register is filling in quickly for a recently listed name. No 13D activist is on the register.
The most recent earnings event, in August, produced a 3.5% one-day move and a 10% five-day move to the upside. The next event is flagged for November 13. Between now and then, the data to watch is whether the short interest build accelerates further — or whether availability begins to tighten meaningfully as the borrow pool shrinks relative to demand, which would change the character of this trade from opportunistic shorting into something with more squeeze risk.
See the live data behind this article on ORTEX.
Open GMRS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
